Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Amgen Acquires Dark Blue Therapeutics in $840M Deal, Expanding Protein Degradation Pipeline

Amgen, a leading biopharmaceutical company, has announced its acquisition of Dark Blue Therapeutics, an Oxford-based biotech startup specializing in protein degradation technology. The deal, which could be worth up to $840 million, significantly bolsters Amgen's oncology portfolio and strengthens its position in the competitive protein degradation field.

NoahAI News1/7/2026

STAAR Surgical Shareholders Reject Alcon's $1.6 Billion Acquisition Offer

STAAR Surgical, a prominent maker of implantable lenses for the eye, will remain an independent company following its shareholders' decision to reject Alcon's revised buyout offer of $1.6 billion. The vote, which took place during a special shareholder meeting, marks the end of a contentious proxy battle and leaves STAAR poised to continue as a stand-alone, publicly traded entity.

NoahAI News1/7/2026

Bright Minds Biosciences Reports Positive Phase 2 Results for Anti-Seizure Drug

Bright Minds Biosciences has announced encouraging phase 2 results for its lead anti-seizure asset, BMB-101, setting the stage for future registrational trials and boosting investor confidence. The serotonin receptor agonist demonstrated significant efficacy in reducing seizures among patients with drug-resistant absence seizures and developmental and encephalopathic epilepsies (DEEs).

NoahAI News1/7/2026

Vicarious Surgical Streamlines Operations with New Software Partnership

Vicarious Surgical, a developer of innovative robotic systems for abdominal procedures, has announced a strategic partnership with an unnamed digital engineering and software development services firm. This collaboration marks a significant step in the company's efforts to streamline operations and accelerate progress towards key milestones.

NoahAI News1/7/2026

Boehringer Ingelheim Expands Kidney Disease Portfolio with $120M Variant Bio Partnership

Boehringer Ingelheim has announced its second major kidney-focused collaboration in recent weeks, signing a deal worth up to $120 million with genomics company Variant Bio. This strategic partnership aims to accelerate the discovery of novel therapies for cardiorenal and kidney diseases by leveraging Variant's AI-powered Inference platform.

NoahAI News1/7/2026

Amgen Acquires Dark Blue Therapeutics in $840 Million Deal, Bolstering Cancer Pipeline

Amgen, the California-based pharmaceutical giant, has announced its acquisition of Dark Blue Therapeutics, a UK biotech company, in a deal worth up to $840 million. This strategic move significantly enhances Amgen's oncology portfolio, particularly in the realm of blood cancer treatments.

NoahAI News1/7/2026

Arrowhead Pharmaceuticals Reports Promising Early Data on Obesity Gene Silencing Candidates

Arrowhead Pharmaceuticals has unveiled encouraging early-phase data on two gene silencing drug candidates targeting obesity, demonstrating potential in fat reduction and weight loss. The company's stock surged following the announcement, reflecting investor optimism in the competitive obesity treatment market.

NoahAI News1/7/2026

Roche Secures $100M GLP-1 License Deal with Structure Therapeutics, Bolstering Obesity Pipeline

Roche has made a strategic move to strengthen its position in the competitive obesity drug market, signing a $100 million licensing agreement with Structure Therapeutics. The deal, announced on January 5, 2026, grants Roche and its subsidiary Genentech a nonexclusive license to certain patents related to CT-996, an oral GLP-1 drug acquired through Roche's recent $2.7 billion acquisition of Carmot Therapeutics.

NoahAI News1/7/2026

RWJBarnabas Health Set to Acquire Englewood Health in $500 Million Deal

In a significant move that continues the trend of healthcare consolidation in New Jersey, RWJBarnabas Health has signed a definitive agreement to acquire Englewood Health. This acquisition, valued at approximately $500 million, is poised to reshape the healthcare landscape in the state's northern counties.

NoahAI News1/7/2026

Instil Bio Discontinues Clinical Development of IMM2510, Returns Rights to ImmuneOnco

Instil Bio, a U.S. biotech company, has announced the discontinuation of its clinical development program for IMM2510, a bispecific antibody combining an anti-PD-L1 antibody with a vascular endothelial growth factor (VEGF) receptor "trap." The company will return the rights to this drug, along with another asset, IMM27M, to their original owner, ImmuneOnco Biopharmaceuticals.

NoahAI News1/7/2026

UK Biotech Ikarovec Partners with VectorBuilder in Potential $1B Deal for Eye Gene Therapy

Ikarovec, a UK-based biotech company, has entered into a promising collaboration with VectorBuilder to develop an innovative eye disease gene therapy that could potentially be administered in doctors' offices. The partnership, which could be worth over $1 billion if finalized, aims to revolutionize the treatment of intermediate age-related macular degeneration (AMD), a condition for which no approved treatments currently exist.

NoahAI News1/7/2026

Naox Technologies Revolutionizes Brain Monitoring with FDA-Cleared In-Ear EEG Device

Naox Technologies has achieved a significant milestone in the field of brain monitoring, securing the first-ever FDA clearance for an in-ear electroencephalography (EEG) device. This breakthrough technology, known as Naox Link, promises to transform the landscape of neurological diagnostics and research by offering a more comfortable and versatile alternative to traditional scalp electrodes.

NoahAI News1/7/2026

«1...7 8 9...67 »